LSA
DNTH icon

Leonteq Securities AG’s Dianthus Therapeutics DNTH Stock Holding History

Leonteq Securities AG’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,500
Closed -$152K – 1225
2023
Q2 		$152K Hold
12,500
– – 0.01% 591
2023
Q1 		$159K Buy
12,500
+1,250
+11% +$13.8K 0.01% 566
2022
Q4 		$71.1K Buy
+11,250
New +$199K ﹤0.01% 748

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Leonteq Securities AG's DNTH Position: Q3 2023 in Review

Leonteq Securities AG sold out of Dianthus Therapeutics (DNTH) in Q3 2023, closing a stake of 12,500 shares — an estimated $152K sold.

Leonteq Securities AG first reported a position in DNTH in Q4 2022 and held it in 3 quarters. The position peaked at $159K in Q1 2023. 30 funds tracked by Wall St. Rank hold DNTH as of Q3 2023.

  • Leonteq Securities AG reported no remaining Dianthus Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Leonteq Securities AG sold 12,500 Dianthus Therapeutics shares in Q3 2023, an estimated $152K.
  • Leonteq Securities AG first reported a position in Dianthus Therapeutics in Q4 2022 and held it in 3 quarters.
  • Leonteq Securities AG's Dianthus Therapeutics position peaked at $159K in Q1 2023.
  • 30 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2023.

Based on Leonteq Securities AG's 13F filing for Q3 2023, filed 11 Mar 2026.